American GLP

State coverage

New York

Medicaid, for obesity: Does not cover. Weight loss has never been a covered reason. Two GLP-1s are covered for other uses, both behind a high BMI.

Denise Ramirez, Coverage Editor · Updated August 2026

New York is not a state that changed its mind. Its own pharmacy program puts it flatly: weight loss is not and never has been a Medicaid-covered indication in New York, and it points at the regulation that says so. There is no reversal here and no bulletin announcing one, which is why New York never appeared on the lists of states that dropped coverage.

What is worth knowing is the part underneath that. New York does pay for two of these drugs — but for reasons that are not weight loss, and behind conditions most people would not clear. Both come with a body mass index requirement well above the threshold in the drug labeling, both require documented lifestyle participation, and both are capped at two treatment attempts in your lifetime.

We are not printing a New York filing deadline on this page. We tried to read the state's own fair-hearing materials on August 31, 2026: health.ny.gov returned 403 Forbidden on all eight paths we tried, and otda.ny.gov refused the connection on all ten, though its robots.txt loaded, so the domain was up and it was the content that would not come. A blocked page is not a published deadline, and a number copied from somewhere else is exactly what this site refuses to do. The federal ceiling that applies everywhere is on the procedures page; your notice carries the number that binds you.

What we could verify for New York

New York's Medicaid pharmacy program excludes GLP-1 drugs when they are used for weight loss, citing the state regulation at 18 NYCRR §505.3(g)(3). Its wording leaves no room: "Weight loss is not and never has been a Medicaid-covered indication. GLP-1 agonists, including but not limited to Ozempic, Wegovy, and Mounjaro are excluded from coverage for weight loss indications."

New York State Department of Health, NYRx, effective July 2026 · source · read August 2026

The state's pharmacy manual says the same thing from the billing side, listing "Drugs used for the treatment of anorexia, weight loss or weight gain" among the categories Medicaid will not reimburse, under the federal statute at SSA §1927(d)(2).

New York State Department of Health, eMedNY, effective March 2026 · source · read August 2026

Wegovy is covered, but not for weight loss. The state's criteria require a confirmed diagnosis of cardiovascular disease, a body mass index the document writes as greater than 40, and confirmation that you are taking part in lifestyle changes that support cardiovascular health. It is capped at two treatment attempts per lifetime.

New York State Department of Health, NYRx, effective July 2026 · source · read August 2026

Zepbound is covered on the same pattern, for obstructive sleep apnea rather than for weight. The criteria require a confirmed OSA diagnosis, a body mass index the document writes as 40 or more, and confirmed participation in lifestyle changes, again capped at two treatment attempts per lifetime.

New York State Department of Health, NYRx, effective July 2026 · source · read August 2026

In New York the answer above is your answer even if you are in a managed care plan. The state moved the pharmacy benefit out of the plans and into NYRx on April 1, 2023, and its letter to pharmacists says the move covers all mainstream managed care plans, including Health and Recovery Plans and HIV Special Needs Plans.

New York State Department of Health, NYRx, effective April 2023 · source · read August 2026

Medicaid is only one of the routes. If you have a commercial or employer plan, the rules are different and are on the employer plans page; Medicare has a federal rule of its own, on the Part D page.

If the appeal fails, or you cannot wait

Cash-pay telehealth is the fallback, not the bargain: you pay the whole cost yourself, and a covered prescription is almost always cheaper than any of these. Use this route when coverage has actually been exhausted, or when you need to start while an appeal runs.

These companies pay us a commission if you start care through the links below. That is how this site is funded, and it does not change what is written above. How we pay for this.

Prices in those notes were read from each company's own site in August 2026 and change often. Check the current number before you buy.

Where this comes from

  1. New York State Department of Health, NYRx, effective July 2026 newyork.fhsc.com/downloads/providers/NYRx_EO_notification_20230913.pdf (read August 2026)
  2. New York State Department of Health, eMedNY, effective March 2026 www.emedny.org/ProviderManuals/Pharmacy/PDFS/Pharmacy_Policy_Guidelines. (read August 2026)
  3. New York State Department of Health, NYRx, effective July 2026 newyork.fhsc.com/downloads/providers/NYRx_EO_notification_wegovy.pdf (read August 2026)
  4. New York State Department of Health, NYRx, effective July 2026 newyork.fhsc.com/downloads/providers/NYRx_EO_notification_zepbound.pdf (read August 2026)
  5. New York State Department of Health, NYRx, effective April 2023 newyork.fhsc.com/downloads/providers/NYRx_provider_notification_20230322 (read August 2026)

Every state we have verified is in the coverage matrix. Appeal routes and deadlines are on the procedures page.